open access

Vol 90, No 1 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-01-31
Get Citation

High tumor cell vimentin expression indicates prolonged survival in patients with ovarian malignant tumors

Sebastian Szubert, Krzysztof Koper, Magdalena Maria Dutsch-Wicherek, Wojciech Jozwicki
DOI: 10.5603/GP.2019.0003
·
Pubmed: 30756366
·
Ginekol Pol 2019;90(1):11-19.

open access

Vol 90, No 1 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-01-31

Abstract

Objectives: The main aims of the study were to investigate the expression of vimentin and its correlation with the overall survival (OS) of patients with malignant ovarian tumors, and the correlation between vimentin expression and tumor stroma characteristics. Material and methods: The study focused on 94 malignant ovarian tumors that had been collected from women who were treated in the Department of Gynecology and Oncology of the Lukaszczyk Oncological Center, Bydgoszcz, Poland. Vimentin expression was assessed in both the cancer cells (expression intensity and quantitative analysis) and the tumor stroma (expression intensity). Vimentin expression was analyzed according to both stromal cellularity and the clinicopatho- logical features of the disease. Results: Both high cancer cell vimentin expression intensity and high quantitative vimentin expression (up to and includ- ing 30% of cells) indicated a significantly prolonged OS. Low vimentin stromal expression was associated with prolonged OS, although the difference did not reach the level of significance. High tumor cell vimentin expression intensity was as- sociated with significantly higher vimentin stromal expression. High vimentin expression in the tumor stroma indicated a significantly higher cellularity of the tumor stroma. Vimentin expression in cancer cells and the tumor stroma were not dependent on the histopathological type, the tumor grade or the FIGO stageof the disease. Conclusions: High cancer cell vimentin expression is associated with an improved OS of patients with malignant ovar- ian tumors. The expression of vimentin in ovarian malignancies may influence the structure of the tumor stroma.

Abstract

Objectives: The main aims of the study were to investigate the expression of vimentin and its correlation with the overall survival (OS) of patients with malignant ovarian tumors, and the correlation between vimentin expression and tumor stroma characteristics. Material and methods: The study focused on 94 malignant ovarian tumors that had been collected from women who were treated in the Department of Gynecology and Oncology of the Lukaszczyk Oncological Center, Bydgoszcz, Poland. Vimentin expression was assessed in both the cancer cells (expression intensity and quantitative analysis) and the tumor stroma (expression intensity). Vimentin expression was analyzed according to both stromal cellularity and the clinicopatho- logical features of the disease. Results: Both high cancer cell vimentin expression intensity and high quantitative vimentin expression (up to and includ- ing 30% of cells) indicated a significantly prolonged OS. Low vimentin stromal expression was associated with prolonged OS, although the difference did not reach the level of significance. High tumor cell vimentin expression intensity was as- sociated with significantly higher vimentin stromal expression. High vimentin expression in the tumor stroma indicated a significantly higher cellularity of the tumor stroma. Vimentin expression in cancer cells and the tumor stroma were not dependent on the histopathological type, the tumor grade or the FIGO stageof the disease. Conclusions: High cancer cell vimentin expression is associated with an improved OS of patients with malignant ovar- ian tumors. The expression of vimentin in ovarian malignancies may influence the structure of the tumor stroma.

Get Citation

Keywords

vimentin; ovarian neoplasms; tumor microenvironment

About this article
Title

High tumor cell vimentin expression indicates prolonged survival in patients with ovarian malignant tumors

Journal

Ginekologia Polska

Issue

Vol 90, No 1 (2019)

Pages

11-19

Published online

2019-01-31

DOI

10.5603/GP.2019.0003

Pubmed

30756366

Bibliographic record

Ginekol Pol 2019;90(1):11-19.

Keywords

vimentin
ovarian neoplasms
tumor microenvironment

Authors

Sebastian Szubert
Krzysztof Koper
Magdalena Maria Dutsch-Wicherek
Wojciech Jozwicki

References (35)
  1. Szymankiewicz M, Dziobek K, Sznajdorwska M, et al. An analysis of the influence of infection on overall survival rates, following modified posterior pelvic exenteration for advanced ovarian cancer. Ginekol Pol. 2018; 89(11): 618–626.
  2. Szymankiewicz M, Koper K, Dziobek K, et al. Microbiological monitoring in patients with advanced ovarian cancer before and after cytoreductive surgery – a preliminary report. Current Issues in Pharmacy and Medical Sciences. 2017; 30(4): 198–202.
  3. Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012; 120(3): 612–618.
  4. Chen Y, Zhang L, Liu W, et al. Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. Biomed Res Int. 2015; 2015: 589301.
  5. Bremnes RM, Dønnem T, Al-Saad S, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011; 6(1): 209–217.
  6. Naito Y, Yoshioka Y, Yamamoto Y, et al. How cancer cells dictate their microenvironment: present roles of extracellular vesicles. Cell Mol Life Sci. 2017; 74(4): 697–713.
  7. Szubert S, Moszynski R, Michalak S, et al. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors. Microvasc Res. 2016; 107: 91–96.
  8. Walentowicz-Sadlecka M, Dziobek K, Grabiec M, et al. The analysis of human leukocyte antigen-G level in patients with endometrial cancer by Western blot technique. Am J Reprod Immunol. 2018 [Epub ahead of print].
  9. Biedka M, Nowikiewicz T, Dziobek K, et al. The analysis of Treg lymphocytes in the blood of patients with breast cancer during the combined oncological treatment. Breast J. 2019; 26(1).
  10. Kakarla S, Song XT, Gottschalk S. Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy. 2012; 4(11): 1129–1138.
  11. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011; 68(18): 3033–3046.
  12. Sommers CL, Walker-Jones D, Heckford SE, et al. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res. 1989; 49(15): 4258–4263.
  13. Wang B, Xi C, Liu M, et al. Breast fibroblasts in both cancer and normal tissues induce phenotypic transformation of breast cancer stem cells: a preliminary study. PeerJ. 2018; 6: e4805.
  14. Díaz-Flores L, Gutiérrez R, Varela H, et al. Microvascular pericytes: a review of their morphological and functional characteristics. Histol Histopathol. 1991; 6(2): 269–286.
  15. Mor-Vaknin N, Punturieri A, Sitwala K, et al. Vimentin is secreted by activated macrophages. Nat Cell Biol. 2003; 5(1): 59–63.
  16. Sato R, Semba T, Saya H, et al. Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets. Stem Cells. 2016; 34(8): 1997–2007.
  17. Kidd ME, Shumaker DK, Ridge KM. The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol. 2014; 50(1): 1–6.
  18. Bauer A, Mylroie H, Thornton CC, et al. Identification of cyclins A1, E1 and vimentin as downstream targets of heme oxygenase-1 in vascular endothelial growth factor-mediated angiogenesis. Sci Rep. 2016; 6: 29417.
  19. Ngan CY, Yamamoto H, Seshimo I, et al. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer. 2007; 96(6): 986–992.
  20. Liu LG, Yan XB, Xie RT, et al. Stromal Expression of Vimentin Predicts the Clinical Outcome of Stage II Colorectal Cancer for High-Risk Patients. Med Sci Monit. 2017; 23: 2897–2905.
  21. Huo Yi, Zheng Z, Chen Y, et al. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells. Oncotarget. 2016; 7(29): 45876–45888.
  22. Jin L, Huo Yi, Zheng Z, et al. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines. Mol Cell Proteomics. 2014; 13(11): 3138–3151.
  23. Du Le, Li J, Lei L, et al. High Vimentin Expression Predicts a Poor Prognosis and Progression in Colorectal Cancer: A Study with Meta-Analysis and TCGA Database. Biomed Res Int. 2018; 2018: 6387810.
  24. Yin S, Chen FF, Yang GF. Vimentin immunohistochemical expression as a prognostic factor in gastric cancer: A meta-analysis. Pathol Res Pract. 2018; 214(9): 1376–1380.
  25. Zou S, Sun H, Fan L, et al. Prognostic indicators in patients with early stage endometrioid adenocarcinoma: a retrospective case-control study of 523 patients. Int J Clin Exp Med. 2017; 10: 3692–8.
  26. Li X, Yang J, Wang X, et al. Role of TWIST2, E-cadherin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression. Eur J Gynaecol Oncol. 2016; 37(1): 100–108.
  27. Slaughter K, Holman LL, Thomas EL, et al. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016; 142(2): 225–230.
  28. Kanakkanthara A, Rawson P, Northcote PT, et al. Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells. Pharm Res. 2012; 29(11): 3022–3032.
  29. Wu JP, Huang WB, Zhou H, et al. Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy. Asian J Androl. 2014; 16(5): 710–714.
  30. Givel AM, Kieffer Y, Scholer-Dahirel A, et al. miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun. 2018; 9(1): 1056.
  31. Szubert S, Szpurek D, Moszynski R, et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer. J Cancer Res Clin Oncol. 2014; 140(3): 361–369.
  32. Cooke VG, LeBleu VS, Keskin D, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012; 21(1): 66–81.
  33. Yeung TL, Leung CS, Yip KP, et al. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol. 2015; 309(7): C444–C456.
  34. Yates B, Zetterberg C, Rajeev V, et al. Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbeta. Exp Cell Res. 2007; 313(17): 3718–3728.
  35. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003; 63(5): 1138–1143.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl